Finerenone in Patients with Focal Segmental Glomerulosclerosis.
Listen to this summary
This prespecified analysis of the FIND-CKD trial asked whether finerenone, a mineralocorticoid receptor antagonist, slows kidney function decline and reduces proteinuria in people with nondiabetic CKD due to focal segmental glomerulosclerosis (FSGS). Among 215 participants with FSGS, finerenone slowed the eGFR decline by 1.3 mL/min/1.73 m²/year versus placebo, lowered urinary protein-to-creatinine ratio by 41% at 12 months, and was well tolerated with a similar rate of hyperkalemia-related events. Although the kidney composite outcome was not statistically significant (HR 0.58, 95% CI 0.30–1.15), these exploratory findings suggest finerenone may be a promising therapy for FSGS warranting confirmation in dedicated trials.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Journal of the American Society of Nephrology : JASN
View all →Nov 19, 2026 · Journal of the American Society of Nephrology : JASN
ZEB1-Mediated ATPAF1 Repression Impairs ATP Synthase Assembly and Promotes Tubular Epithelial Plasticity in CKD.
Nov 13, 2026 · Journal of the American Society of Nephrology : JASN
Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN.
Nov 13, 2026 · Journal of the American Society of Nephrology : JASN
Endoplasmic Reticulum Membrane Insertion of APOL1 Risk Alleles Disrupts Calcium Homeostasis and Is Mitigated by Autophagic Clearance.
Nov 13, 2026 · Journal of the American Society of Nephrology : JASN
Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy.
Nov 12, 2026 · Journal of the American Society of Nephrology : JASN
Implementation Strategies to Improve CKD Testing and Delivery of Guideline-Directed Medical Therapy: A Scoping Review.
Nov 9, 2026 · Journal of the American Society of Nephrology : JASN
Pathogenic Gd-IgA1: Redefining the Role of Galactose-Deficient IgA1 in IgA Nephropathy.
More in Pediatrics
View all →Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer.
Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Effect of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Persistent Fatigue: A Randomized Controlled Trial (the REFUEL trial).
Nov 20, 2026 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316).
Nov 20, 2026 · Hormone research in paediatrics
Post-Menarcheal Height Gain After Gonadotropin-Releasing Hormone Agonist Treatment in Girls with Central Precocious Puberty.
Nov 20, 2026 · Hormone research in paediatrics
JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN WITH TYPE 1 DIABETES: IMPACT OF CURRENT MEDICAL TREATMENT OPTIONS ON ANTHROPOMETRY AND METABOLIC CONTROL.
Nov 20, 2026 · European heart journal
Acute pulmonary embolism: long-term cause-specific mortality in a Chinese nationwide registry.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


